8-K: Lifecore Biomedical Reports Strong Q3 Revenue Growth

Lifecore Biomedical, Inc. announced a 26% increase in revenue for the three months ended September 30, 2025, alongside significant operational efficiencies and new program signings.

Summary

• Revenue for the three months ended September 30, 2025, was $31.1 million, representing a 26% increase from $24.7 million in the comparable prior period ended August 25, 2024.
• HA manufacturing revenues increased by $4.8 million, primarily due to increased demand from a customer's supply chain initiatives.
• CDMO revenues increased by $1.6 million, driven by $2.6 million higher sales volumes and $0.3 million pricing, partially offset by $1.3 million lower development revenue.
• Gross profit for the three months ended September 30, 2025, was $7.8 million, up from $5.4 million in the comparable prior period.
• Selling, general and administrative (SG&A) expenses decreased by $5.9 million to $8.9 million, from $14.8 million in the comparable prior period, including reductions in recurring and non-recurring expenses.
• Net loss for the three months ended September 30, 2025, was $10.0 million, or $0.29 per diluted share, an improvement from a net loss of $16.2 million, or $0.53 per diluted share, in the comparable prior period.
• Adjusted EBITDA for the three months ended September 30, 2025, was $3.1 million, a $4.9 million increase from a negative $1.8 million in the comparable prior period.
• The company signed two new programs during the quarter, including one late-stage and one early-stage program, and an additional two programs subsequent to quarter end, including a commercial site transfer with a large multinational pharmaceutical company.
• Workforce productivity in manufacturing improved by more than 20% over approximately the past year.
• Lifecore is moving its fiscal year end to align with the calendar year, effective for the December 31, 2025, calendar period.
• Guidance for the approximately seven-month transition period (May 26 to December 31, 2025) projects revenue of $74 to $76 million, net loss of $18.4 million to $16.4 million, and Adjusted EBITDA of $12 to $14 million.

Sentiment

Score: 8

Explanation: The filing reports strong financial improvements with significant revenue growth, reduced losses, and positive Adjusted EBITDA. Operational efficiencies and new business wins are positive indicators. While a net loss persists and interest expense increased, the overall trajectory and future outlook are optimistic, supported by strategic initiatives and market growth.

Positives

• Revenue increased by 26% to $31.1 million for the three months ended September 30, 2025, compared to the prior comparable period.
• Adjusted EBITDA significantly improved by $4.9 million to $3.1 million, from a negative $1.8 million in the prior comparable period.
• Net loss decreased to $10.0 million from $16.2 million in the prior comparable period, indicating improved financial performance.
• Selling, general and administrative expenses decreased substantially by $5.9 million, reflecting focus on cost management.
• Signed multiple new programs, including a late-stage program and a commercial site transfer with a large multinational pharmaceutical company, diversifying the pipeline.
• Workforce productivity in manufacturing improved by over 20% in the past year, demonstrating operational efficiency gains.
• Qualified a new hyaluronic acid (HA) specification and completed stability batches for the Asian market, expanding international market access.
• Hired a seasoned industry executive as Head of Business Transformation to drive cost structure improvements and productivity.
• Successfully passed a general FDA audit in March 2025, affirming quality systems.
• Expanded capacity with a new 5-head isolator filler, expected to increase annual production capacity by approximately 100%.

Negatives

• The company reported a net loss of $10.0 million for the three months ended September 30, 2025.
• Interest expense, net, increased to $6.3 million from $5.4 million in the comparable prior period, primarily due to Alcon term loans.
• CDMO gross profit declined by $1.9 million, attributed to lower development revenue and changes in product mix and costing.
• The debt derivative liability, related party, increased to $25,491 thousand as of September 30, 2025, from $24,991 thousand as of May 25, 2025.
• Accumulated deficit increased to $(218,095) thousand as of September 30, 2025, from $(205,240) thousand as of May 25, 2025.

Risks

• The timing and amount of future expenses, revenue, Adjusted EBITDA, cash flow, and capital requirements are uncertain.
• The timing and availability of, and the need for, additional financing pose a risk.
• The ability to maintain or expand relationships with current customers, including the impact of changes in consumer demand for manufactured products, is a factor.
• The ability to grow and diversify the business with new customers, including the potential loss of development customers due to funding or regulatory approval issues, is a challenge.
• Compliance with covenants under credit agreements and the ability to make required interest and principal payments when due are critical.
• The ability to raise additional capital for ongoing needs through equity, debt, collaborations, strategic alliances, or licensing arrangements is not guaranteed.
• Macroeconomic events or circumstances, such as inflation, tariffs, interest rates, social unrest, and global instability, could impact operations and financial performance.
• The performance of third-party suppliers is a potential risk.
• Pharmaceutical industry market forces may impact customer success and continued demand for products.
• The ability to recruit or retain key scientific, technical, business development, and management personnel and executive officers is important.
• Compliance with stringent U.S. and foreign government regulations in pharmaceutical manufacturing, including cGMP, is essential.
• The outcome and cost of existing and any new litigation or regulatory proceedings could materially affect results.
• Other risk factors detailed in the company's SEC filings, including the Annual Report on Form 10-K for the year ended May 25, 2025, could cause actual results to differ materially.

Future Outlook

The company is affirming its guidance for the approximately seven-month transition period from May 26 through December 31, 2025, expecting revenue of $74 to $76 million, net loss of $18.4 million to $16.4 million, and Adjusted EBITDA of $12 to $14 million. Management aims for a 12+% revenue CAGR and Adjusted EBITDA margins over 25% in the mid-term, driven by maximizing existing customer business, advancing late-stage pipeline programs towards commercialization, and winning impactful new business. A significant inflection point in existing commercial customer demand is expected in 2027, with projected doubling of injectable unit demand from largest customers.

Management Comments

• "We are thrilled with the progress made during this period. Guiding this progress is our three-pronged strategy for growth which is comprised of: maximizing our existing customer business, advancing programs currently within our late-stage development pipeline towards commercialization, and finally, winning impactful new business that will continue to fill our project pipeline from early-stage work to commercial site transfers. We believe this strategy will allow us to reach our goals of achieving a 12+% revenue CAGR and increasing Adjusted EBITDA* margins to more than 25% over the mid-term, and the results we have seen to date support our optimism." Paul Josephs, President and Chief Executive Officer of Lifecore.
• "Financial outcomes during the period were strong, as we recorded a 26% increase in revenue as compared to the prior year comparable period, along with significant improvements in SG&A expense. These financial results reflect our focus on improving workforce productivity by implementing initiatives which drive continued improvements. We are very pleased with the progress made during the period, which we believe has put us on the path to achieving growth and sustainable profitability in the years ahead." Paul Josephs, President and Chief Executive Officer of Lifecore.

Industry Context

Lifecore Biomedical operates within the robust and expanding Contract Development and Manufacturing Organization (CDMO) industry, specifically targeting the Global Injectable CDMO market, valued at $10 billion with a 10% CAGR, and the broader Global CDMO market, at $120 billion with an 8% CAGR. The company is also a leader in the Hyaluronic Acid (HA) market, a $9.8 billion sector growing at a 7% CAGR. The increasing demand for injectables, which constitute over 50% of annual US drug approvals, and the acceleration of US-based manufacturing, provide strong tailwinds. Lifecore's strategic expansion into new modalities beyond ophthalmic therapeutics, including GLP-1 peptides, and its investment in advanced manufacturing capabilities like the 5-head isolator filler, align with these high-growth industry trends and position it to capitalize on the projected 10X increase in the GLP-1 market.

Comparison to Industry Standards

• The Global Injectable CDMO market is valued at $10 billion with a projected 10% Compound Annual Growth Rate (CAGR). Lifecore's goal of achieving a 12%+ revenue CAGR over the mid-term indicates an ambition to outpace the general market growth.
• The Hyaluronic Acid (HA) market is a $9.8 billion market with a 7% CAGR. Lifecore, as a leading manufacturer of injectable-grade HA, is well-positioned within this growing segment.
• The broader Global CDMO market is a $120 billion market with an 8% CAGR. Lifecore's targeted 12%+ revenue CAGR suggests a strategy to capture a larger share of this market.
• The GLP-1 market, currently $47 billion, is expected to increase 10X, presenting a significant growth opportunity that Lifecore is targeting by diversifying its pipeline into new modalities.
• Over 50% of annual US drug approvals are injectables, highlighting a strong and sustained demand for the specialized services Lifecore provides.
• Lifecore's expanded capacity with a new 5-head isolator filler, which increases annual production capacity by approximately 100%, positions it to meet the growing demand for sterile injectable products, aligning with industry trends towards increased manufacturing capabilities and onshoring initiatives.

Management Changes

Corporate Governance

Legal Proceedings

• The company's risk factors include the "outcome and cost of existing and any new litigation or regulatory proceedings."
• Selling, general and administrative expenses in the prior comparable period included legal fees related to a stockholder activist settlement, and current period expenses included reductions in non-recurring expenses primarily related to legacy matters, implying past legal/regulatory issues.

Related Party Transactions

• Accounts receivable, related party, decreased to $7,175 thousand as of September 30, 2025, from $13,537 thousand as of May 25, 2025.
• Debt, net of current portion, related party, increased to $129,263 thousand as of September 30, 2025, from $121,198 thousand as of May 25, 2025.
• Debt derivative liability, related party, increased to $25,491 thousand as of September 30, 2025, from $24,991 thousand as of May 25, 2025.
• Revenues, related party, increased to $11,816 thousand for the three months ended September 30, 2025, from $7,912 thousand for the comparable prior period.
• Interest expense, related party, increased to $(5,833) thousand for the three months ended September 30, 2025, from $(4,400) thousand for the comparable prior period.
• Change in fair value of debt derivative liability, related party, was $(375) thousand for the three months ended September 30, 2025, compared to $900 thousand for the comparable prior period.

Stakeholder Impact

• **Shareholders**: The strong financial performance, including significant revenue growth and improved Adjusted EBITDA, along with strategic growth initiatives and a positive future outlook, could positively impact shareholder value. The fiscal year change aims to provide more timely and comparable reporting.
• **Employees**: Improved workforce productivity and a performance-driven culture suggest a focus on efficiency and potentially performance-based incentives. The creation of a new 'Head of Business Transformation' role indicates investment in organizational development.
• **Customers**: New program signings, qualification of new HA specifications for the Asian market, and completion of stability batches for regulatory approval demonstrate enhanced capabilities and commitment to serving customer needs, particularly for international market expansion and complex formulations.
• **Creditors**: Increased related-party debt and interest expense, while offset by improved EBITDA, will be a focus. The company's ability to comply with credit agreement covenants is a stated risk.
• **Suppliers**: Plans for aggressive procurement strategies to maximize efficiencies could influence supplier relationships and terms.

Next Steps

• Launch of the new enterprise resource planning (ERP) system, expected to go live in Q1 2026, to strengthen inventory control, support sharper financial management, and help reduce costs.
• Announce results for the three-month period ended December 31, 2025, and the approximately seven-month transition period from May 26 to December 31, 2025, in March 2026.
• Further maximize efficiencies and productivity via aggressive procurement and organizational strategies.
• Support a significant inflection point in existing commercial customer demand in 2027, where injectable unit demand from largest customers is projected to more than double.
• Advance programs currently within the late-stage development pipeline towards commercialization.
• Win impactful new business that will continue to fill the project pipeline, from early-stage work to commercial site transfers.

Key Dates

Recommendation

Lifecore Biomedical has demonstrated strong operational and financial momentum, with a 26% increase in revenue and a significant turnaround in Adjusted EBITDA from negative to positive. The company's strategic focus on maximizing existing customer business, advancing its late-stage pipeline, and securing new high-value contracts, including a commercial site transfer with a large multinational pharmaceutical company, positions it for sustained growth. Operational efficiencies, such as a 20% improvement in manufacturing productivity and the expansion of capacity with a new isolator filler, underscore a commitment to profitability. While a net loss persists and interest expenses are notable, the clear path to achieving mid-term goals of 12%+ revenue CAGR and 25%+ Adjusted EBITDA margins, coupled with a strong leadership team and successful regulatory audits, makes this an attractive investment for long-term growth.

Keywords

CDMO, contract development and manufacturing, sterile injectables, hyaluronic acid, HA, pharmaceutical, biotechnology, financial results, earnings, Q3 2025, Lifecore Biomedical, LFCR, manufacturing productivity, enterprise resource planning, ERP, corporate update, investor presentation, adjusted EBITDA, revenue growth